Drug intelligence / Profile preview

BCD-148

Development stage: Phase 3
Lead developer: Biocad
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

BCD-148 is a biosimilar of eculizumab, a humanized monoclonal antibody that targets complement protein C5. It acts as a complement C5 inhibitor, blocking complement activation to treat paroxysmal nocturnal hemoglobinuria (PNH). Developed by Biocad, BCD-148 is administered intravenously and is intended as an alternative to the originator drug Soliris® (eculizumab). The drug has undergone Phase 1 and Phase 3 clinical trials in Russia for PNH treatment but has not yet received approval. Its mechanism of action involves inhibition of the complement cascade at the C5 component, preventing formation of membrane attack complex and subsequent hemolysis.

Other names: Eculizumab biosimilar

Targets

Beyond the preview

Go deeper on BCD-148.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BCD-148.

Explore the full profile